top of page
Executive Spotlights

Michael Aldridge, Seasoned Biotech Executive, Appointed CEO of Focal Medical

Raleigh, NC, November 1, 2022 (Business Wire) -- Focal Medical, Inc. (formerly Advanced Chemotherapy Technologies, Inc.), a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative local drug delivery technology platform, today announced the appointment of Michael Aldridge as the Company’s new Chief Executive Officer. Michael joins Focal Medical with more than 25 years of experience in the biopharma industry. He succeeds Tony Voiers, who assumes the role of Chief Operating Officer.


Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma

Comments


Life Science Headlines
bottom of page